Q3 2023 · 13F-HR
RA CAPITAL MANAGEMENT, L.P.holdings as filed
Filed 2023-11-14 · accession 0001104659-23-118214
$5.04B
Reported value
65
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S - ADR | $1.00B | 19.9% | 10,719,555 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP-ADR | $420.8M | 8.35% | 6,264,707 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $402.3M | 7.98% | 7,891,254 | Common | SOLE |
| 45253H101 | IMGNEUR | IMMUNOGEN INC | $211.4M | 4.19% | 13,322,288 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $176.3M | 3.50% | 11,416,948 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $137.0M | 2.72% | 532,892 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $130.1M | 2.58% | 5,676,067 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $112.1M | 2.22% | 8,263,982 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $103.5M | 2.05% | 6,940,000 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC - ADR | $103.0M | 2.04% | 6,317,990 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $99.6M | 1.98% | 7,236,454 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $98.9M | 1.96% | 17,202,009 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $97.9M | 1.94% | 46,202,425 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $95.8M | 1.90% | 7,809,852 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $92.4M | 1.83% | 9,165,652 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $89.3M | 1.77% | 5,551,295 | Common | SOLE |
| 45720L107 | INBXUSD | INHIBRX INC | $86.7M | 1.72% | 4,724,207 | Common | SOLE |
| 78349D107 | RXST | RXSIGHT INC | $85.1M | 1.69% | 3,052,796 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $83.3M | 1.65% | 9,000,000 | Common | SOLE |
| 30050B101 | EVH | EVOLENT HEALTH INC - A | $74.5M | 1.48% | 2,736,680 | Common | SOLE |
| N2451R105 | CVAC | CUREVAC NV | $72.4M | 1.44% | 10,604,344 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $69.9M | 1.39% | 1,000,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $62.6M | 1.24% | 6,416,147 | Common | SOLE |
| 00509G209 | ABOS | ACUMEN PHARMACEUTICALS INC | $62.0M | 1.23% | 14,932,063 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $58.4M | 1.16% | 18,472,503 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $56.2M | 1.11% | 5,587,333 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $53.7M | 1.07% | 4,691,178 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $53.0M | 1.05% | 4,163,211 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $51.5M | 1.02% | 11,609,704 | Common | SOLE |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $48.4M | 0.96% | 4,417,259 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $48.2M | 0.96% | 22,748,880 | Common | SOLE |
| 45114M109 | — | ICOSAVAX INC | $46.2M | 0.92% | 5,963,565 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $46.0M | 0.91% | 4,810,508 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $42.1M | 0.84% | 1,977,901 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $41.3M | 0.82% | 8,131,952 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $40.9M | 0.81% | 6,416,998 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $36.6M | 0.73% | 1,239,000 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $35.8M | 0.71% | 9,459,678 | Common | SOLE |
| 28658R106 | CLYM | ELIEM THERAPEUTICS INC | $34.6M | 0.69% | 13,150,849 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $30.8M | 0.61% | 2,007,946 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $30.6M | 0.61% | 1,762,000 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $30.2M | 0.60% | 3,178,476 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $30.1M | 0.60% | 4,398,453 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $29.9M | 0.59% | 204,500 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $29.0M | 0.58% | 2,122,465 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $26.9M | 0.53% | 3,370,506 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $20.8M | 0.41% | 1,483,697 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $17.1M | 0.34% | 6,718,483 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC-ADR | $16.1M | 0.32% | 800,000 | Common | SOLE |
| 95075A107 | HOWL | WEREWOLF THERAPEUTICS INC | $13.2M | 0.26% | 6,144,881 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $12.8M | 0.25% | 1,400,001 | Common | SOLE |
| 640268108 | NKTREUR | NEKTAR THERAPEUTICS | $11.1M | 0.22% | 18,700,000 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $10.8M | 0.22% | 7,805,129 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $10.1M | 0.20% | 3,525,754 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $9.5M | 0.19% | 1,286,000 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $8.6M | 0.17% | 3,426,286 | Common | SOLE |
| 449585108 | 1K0 | IGM BIOSCIENCES INC | $7.8M | 0.16% | 937,500 | Common | SOLE |
| 87410C104 | — | TALARIS THERAPEUTICS INC | $6.8M | 0.13% | 2,403,238 | Common | SOLE |
| 16934W106 | CMRXEUR | CHIMERIX INC | $6.2M | 0.12% | 6,501,624 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $6.1M | 0.12% | 961,863 | Common | SOLE |
| 207523101 | — | CONNECT BIOPHARMA HOLDINGS L | $5.7M | 0.11% | 6,991,003 | Common | SOLE |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $3.0M | 0.06% | 3,470,688 | Common | SOLE |
| 63009R109 | NSTGEUR | NANOSTRING TECHNOLOGIES INC | $3.0M | 0.06% | 1,723,373 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $1.6M | 0.03% | 342,000 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA CO NV-27 | $633,333 | 0.01% | 333,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.